HK1003051A1 - Treatment and prophylaxis of pancreatitis - Google Patents

Treatment and prophylaxis of pancreatitis

Info

Publication number
HK1003051A1
HK1003051A1 HK98102164A HK98102164A HK1003051A1 HK 1003051 A1 HK1003051 A1 HK 1003051A1 HK 98102164 A HK98102164 A HK 98102164A HK 98102164 A HK98102164 A HK 98102164A HK 1003051 A1 HK1003051 A1 HK 1003051A1
Authority
HK
Hong Kong
Prior art keywords
pancreatitis
treatment
prophylaxis
troglitazone
prevention
Prior art date
Application number
HK98102164A
Other languages
English (en)
Inventor
Toshihiko Fujiwara
Hiroyoshi Horikoshi
Masaharu Fukami
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HK1003051A1 publication Critical patent/HK1003051A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catching Or Destruction (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
HK98102164A 1996-03-18 1998-03-16 Treatment and prophylaxis of pancreatitis HK1003051A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6106396 1996-03-18
JP25020196 1996-09-20

Publications (1)

Publication Number Publication Date
HK1003051A1 true HK1003051A1 (en) 1998-10-09

Family

ID=26402115

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98102164A HK1003051A1 (en) 1996-03-18 1998-03-16 Treatment and prophylaxis of pancreatitis

Country Status (19)

Country Link
US (1) US5753681A (xx)
EP (1) EP0796618B1 (xx)
KR (1) KR100542778B1 (xx)
CN (1) CN1178657C (xx)
AT (1) ATE212548T1 (xx)
AU (1) AU708315B2 (xx)
CA (1) CA2200126C (xx)
CZ (1) CZ283968B6 (xx)
DE (1) DE69710111T2 (xx)
DK (1) DK0796618T3 (xx)
ES (1) ES2167678T3 (xx)
HK (1) HK1003051A1 (xx)
HU (1) HUP9700598A3 (xx)
ID (1) ID16266A (xx)
IL (1) IL120443A (xx)
NO (1) NO313179B1 (xx)
NZ (1) NZ314406A (xx)
PT (1) PT796618E (xx)
TW (1) TW548102B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
CN1255386C (zh) * 1997-10-08 2006-05-10 三共株式会社 有取代稠合杂环化合物
SK161499A3 (en) 1998-03-30 2000-06-12 Japan Tobacco Inc Process for producing isooxazolidinedione compound
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド グリコーゲンシンターゼキナーゼ3のインヒビター
IL140664A0 (en) * 1998-07-21 2002-02-10 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
EP1213287B1 (en) 1999-08-23 2005-05-25 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
DE60020573T2 (de) 1999-08-23 2006-03-16 Kyorin Pharmaceutical Co., Ltd. Substituierte benzylthiazolidin-2,4-dion derivate
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MA33248B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Traitement de troubles résistant à l'insuline

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3343141A1 (de) * 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4703052A (en) * 1985-05-21 1987-10-27 Pfizer Inc. Hypoglycemic thiazolidinediones
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
DK375789A (da) * 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
AU7118694A (en) * 1993-07-13 1995-02-13 Janica M. Moizis Fastener for clothing
DK0684242T3 (da) * 1993-12-27 1999-11-01 Japan Tobacco Inc Isoxazolidindionderivat og anvendelse deraf
NO305987B1 (no) * 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
FR2721608B1 (fr) * 1994-06-22 1996-07-19 Rhone Poulenc Rorer Sa Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
US5703096A (en) * 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem

Also Published As

Publication number Publication date
IL120443A (en) 2000-07-16
NO971219L (no) 1997-09-19
EP0796618B1 (en) 2002-01-30
HU9700598D0 (en) 1997-05-28
ES2167678T3 (es) 2002-05-16
CN1178657C (zh) 2004-12-08
DE69710111T2 (de) 2002-10-02
US5753681A (en) 1998-05-19
IL120443A0 (en) 1997-07-13
EP0796618A1 (en) 1997-09-24
NO971219D0 (no) 1997-03-17
HUP9700598A2 (hu) 1998-09-28
CZ79097A3 (en) 1997-10-15
NO313179B1 (no) 2002-08-26
CA2200126C (en) 2006-08-15
HUP9700598A3 (en) 1998-10-28
KR100542778B1 (ko) 2006-04-14
CZ283968B6 (cs) 1998-07-15
PT796618E (pt) 2002-06-28
ID16266A (id) 1997-09-18
DK0796618T3 (da) 2002-05-06
TW548102B (en) 2003-08-21
CA2200126A1 (en) 1997-09-18
KR19980023975A (ko) 1998-07-06
AU708315B2 (en) 1999-07-29
DE69710111D1 (de) 2002-03-14
MX9702058A (es) 1998-03-31
AU1628597A (en) 1997-09-25
NZ314406A (en) 2000-12-22
CN1170575A (zh) 1998-01-21
ATE212548T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
PL304649A1 (en) Novel derivatives of taxane and pharmaceutical agents
HK1003051A1 (en) Treatment and prophylaxis of pancreatitis
HRP950288A2 (en) Oxalylamino-benzofuran- and benzothienyl-derivatives
TW269678B (xx)
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
CY2543B1 (en) 9-Ä(Substituted glycyl)amidoÜ-6-(substituted)-5-hydroxy-6-deoxytetracyclines
AU6452194A (en) Pharmaceutical agents for treatment of emesis
AU658296B2 (en) 7 beta-substituted-4-aza-5 alpha-cholestan-3-ones as 5 alpha-reductase inhibitors
ZA974984B (en) New substituted thiazolidine-2,4-dione derivatives, processes for the obtaining thereof, and pharmaceutical compositions containing them.
WO2000021513A3 (en) Methods for treating multiple sclerosis
AU4694999A (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
SI1187612T1 (en) Use of riluzole for the treatment of multiple sclerosis
AU3737289A (en) Agent for treating pancreatitis or the like
AU8149594A (en) Methylene blue for the treatment or prophylaxis of encephalopathy caused by ifosfamide
AU3744100A (en) Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
EP0950411B8 (de) Verfahren zur Herstellung eines Extraktes aus Copalchirinde und Verwendung der Neoflavonoide zur Behandlung von Diabetes
IL110925A0 (en) Process for the preparation of 1,2-benzisothiazoles
EP0626379A3 (de) Verfahren zur Herstellung von 2-Chlor-benzothiazolen oder 2-Chlor-benzoxazolen.
WO2000007582A3 (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
WO2001047522A3 (fr) Association de deoxyfructosazine et d'un antidiabetique de la famille des biguanides
GB9323550D0 (en) Composition for the treatment of hydrothyroidism

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070317